ArticleNature2024
A disease-associated gene desert directs macrophage inflammation through ETS2.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed.
- A human single-cell atlas identifies OLR1Nature genetics · 2026Article
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Regulation of Inducible Nitric Oxide Synthase (NOS2) Expression in Healthy and Inflamed Bowel: A Narrative Review.International journal of molecular sciences · 2026Review
- IL1B-high macrophages promote ferroptosis-like lipid peroxidation injury in Crohn's disease intestinal epithelium.Redox biology · 2026Article
- Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn's disease.Nature immunology · 2026Article
- Microbiota-derived 4-HPAA alleviates Crohn's disease by stabilizing SIRT1 and reprogramming macrophage immunometabolism.Apoptosis : an international journal on programmed cell death · 2026Article
- Multi-level transcriptional control of specific macrophage responses.The EMBO journal · 2026Review
- Caveola and Its Resident Proteins, Caveolin-1 and -2, Play Critical Roles in the Pathogenesis of nAMD and PCV.Investigative ophthalmology & visual science · 2026Article
- Anti-Inflammatory Components ofFoods (Basel, Switzerland) · 2026Article
- Macrophage signaling associates with fibrogenic program activation in periductal fibroblasts in pediatric primary sclerosing cholangitis.JCI insight · 2026Article
- Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.The Journal of experimental medicine · 2026Article
- Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn's disease pathogenesis.Nature genetics · 2026Article
- The Immune-Chemokine Axis in Alzheimer's Disease: Roles of Adaptive Immune System in Neuroinflammation and Disease Progression.Biomolecules · 2026Review
- Ultra-fast genetic colocalisation across millions of association signals.PLoS genetics · 2026Article
- ETS‑1/ETS‑2 transcription factors in CVD (Review).International journal of molecular medicine · 2026Review
- Identifying and targeting abnormal mitochondrial localization associated with psychosis.bioRxiv : the preprint server for biology · 2026Article
- Connecting polygenic disease risk to cell states and regulatory programs through single-cell chromatin accessibility.bioRxiv : the preprint server for biology · 2026Article
- Conserved noncoding sequence-9 regulates NFATc1-mediated IL-10 expression in B cells to control inflammatory responses.Science advances · 2026Article
- Article
- Current Perspectives on the Inflammatory Bowel Disease Pathogenesis of Microbiota and the Gut-Brain Axis, and Emerging Therapeutics.Biomedicines · 2026Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byETS2 drives IBD.2024
Authors and funding
43 authors.
C T Stankey *Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-5710-1716
C Bourges *Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-8122-0475
L M Haag *Division of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-3754-5317
T Turner-StokesGenetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.
A P PiedadeGenetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.
C Palmer-JonesDepartment of Gastroenterology, Royal Free Hospital, London, UK.
I PapaGenetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0003-3167-7623
M Silva Dos SantosMetabolomics STP, The Francis Crick Institute, London, UK.ORCID 0000-0003-2404-8490
Q ZhangGenomics of Inflammation and Immunity Group, Human Genetics Programme, Wellcome Sanger Institute, Hinxton, UK.
A J CameronWolfson Wohl Cancer Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-7065-9033
A LegriniWolfson Wohl Cancer Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
T ZhangWolfson Wohl Cancer Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
C S WoodWolfson Wohl Cancer Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
F N NewNanoString Technologies, Seattle, WA, USA.ORCID 0000-0001-6213-4731
L O RandzavolaDepartment of Immunology and Inflammation, Imperial College London, London, UK.
L SpeidelAncient Genomics Laboratory, The Francis Crick Institute, London, UK.
A C BrownWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
A HallThe Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK.
F SaffiotiInstitute for Liver and Digestive Health, Division of Medicine, University College London, London, UK.ORCID 0000-0001-7635-9931
E C ParkesGenetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.
W EdwardsCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
H DireskeneliDepartment of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey.
P C GraysonSystemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, USA.
L JiangDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China.
P A MerkelDivision of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
G Saruhan-DireskeneliDepartment of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.ORCID 0000-0002-6903-7173
A H SawalhaDivision of Rheumatology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-3884-962X
E TombettiDepartment of Biomedical and Clinical Sciences, Milan University, Milan, Italy.
A QuagliaDepartment of Cellular Pathology, Royal Free Hospital, London, UK.
D ThorburnInstitute for Liver and Digestive Health, Division of Medicine, University College London, London, UK.
J C KnightWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-0377-5536
A P RochfordDepartment of Gastroenterology, Royal Free Hospital, London, UK.
C D MurrayDepartment of Gastroenterology, Royal Free Hospital, London, UK.
P DivakarNanoString Technologies, Seattle, WA, USA.
M GreenExperimental Histopathology STP, The Francis Crick Institute, London, UK.
E NyeExperimental Histopathology STP, The Francis Crick Institute, London, UK.
J I MacRaeMetabolomics STP, The Francis Crick Institute, London, UK.ORCID 0000-0002-1464-8583
N B JamiesonWolfson Wohl Cancer Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-9552-4725
P SkoglundAncient Genomics Laboratory, The Francis Crick Institute, London, UK.
M Z CaderCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
C WallaceCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.ORCID 0000-0001-9755-1703
D C ThomasCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.ORCID 0000-0002-9738-2329
J C LeeGenetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK. james.lee@crick.ac.uk.ORCID 0000-0001-5711-9385
Funding
Characterizing the Takayasu Arteritis Genetic Risk in RPS9/LILRB3R01AR070148 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SAWALHA, AMR H · 2017 to 2022
$1.7MMedical Research Council MR/V029711/1NIAMS NIH HHS R01 AR070148Wellcome Trust CC2219Wellcome Trust FC001595
Abstract
Increasing rates of autoimmune and inflammatory disease present a burgeoning threat to human health
Indexed as
InflammationMacrophagesProto-Oncogene Protein c-ets-2Anti-Inflammatory AgentsCells, CulturedChromosomes, Human, Pair 21Databases, FactualFemaleGene Expression RegulationGenome-Wide Association StudyGenomicsHaplotypesHumansInflammatory Bowel DiseasesInterleukin-23MaleAnti-Inflammatory AgentsETS2 protein, humanInterleukin-23Proto-Oncogene Protein c-ets-2Tumor Necrosis Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.